Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.20.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 5,223 $ 9,295
Restricted cash 0 361
Receivables 993 1,737
Inventory 998 1,262
Contract assets 0 99
Prepaid expenses and other current assets 1,094 547
Total current assets 8,308 13,301
Property and equipment, net 817 794
Operating lease right-of-use asset 397 0
Total assets 9,522 14,095
Current liabilities:    
Accounts payable 1,401 1,526
Accrued clinical trials expenses 309 620
Accrued sales allowances 809 0
Other accrued liabilities 809 466
Operating lease liability, current 272 0
Deferred revenue 0 313
Current portion of long-term debt, net of debt discount of $0 and $123 0 527
Total current liabilities 3,600 3,452
Long-term debt, net of debt discount of $346 and $543 4,019 3,787
Warrant liability 320 0
Derivative liability 0 25
Operating lease liability, non-current 150 0
Total liabilities 8,089 7,264
Commitments and contingencies (Note 5)
Stockholders' (deficit) equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2019 and 2018. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 125,000,000 shares authorized 57,378,794 and 13,010,292 shares issued and outstanding at December 31, 2019 and 2018, respectively. 57 13
Additional paid-in capital 350,413 339,397
Accumulated deficit (349,037) (332,579)
Total stockholders' equity 1,433 6,831
Total liabilities and stockholders' equity $ 9,522 $ 14,095